The association of AGTR2 polymorphisms with preeclampsia and uterine artery bilateral notching is modulated by maternal BMI by Zhou, A. et al.
 ACCEPTED VERSION  
 
 
Zhou, Ang; Dekker, Gustaaf Albert; Lumbers, Eugenie Ruth; Leemaqz, Shalem Yiner-Lee; 
Thompson, Steven David; McCowan, Lesley M. E.; Roberts, Claire Trelford  
The association of AGTR2 polymorphisms with preeclampsia and uterine artery bilateral 
notching is modulated by maternal BMI  
Placenta, 2013; 34(1):75-81     
 
© 2012 Elsevier Ltd. All rights reserved. 
 
NOTICE: this is the author’s version of a work that was accepted for publication in Placenta. 
Changes resulting from the publishing process, such as peer review, editing, corrections, 
structural formatting, and other quality control mechanisms may not be reflected in this 
document. Changes may have been made to this work since it was submitted for 
























Elsevier's AAM Policy: Authors retain the right to use the accepted author manuscript 
for personal use, internal institutional use and for permitted scholarly posting provided 
that these are not for purposes of commercial use or systematic distribution. 
Elsevier believes that individual authors should be able to distribute their AAMs for their 
personal voluntary needs and interests, e.g. posting to their websites or their 
institution’s repository, e-mailing to colleagues. However, our policies differ regarding 
the systematic aggregation or distribution of AAMs to ensure the sustainability of the 
journals to which AAMs are submitted. Therefore, deposit in, or posting to, subject-
oriented or centralized repositories (such as PubMed Central), or institutional 
repositories with systematic posting mandates is permitted only under specific 
agreements between Elsevier and the repository, agency or institution, and only 
consistent with the publisher’s policies concerning such repositories. 
 
3 February 2014 
1 
 
The association of AGT2R polymorphisms with preeclampsia and 1 
uterine artery bilateral notching is modulated by maternal BMI 2 
Ang Zhou
1
, Gustaaf A Dekker
1,2
, Eugenie R Lumbers
3
, Shalem Y Lee
1
, Steven D Thompson
1
, 3 
Lesley M E McCowan
4
, Claire T Roberts
1
 On behalf of the SCOPE consortium 4 
1
Robinson Institute, University of Adelaide, Adelaide, Australia 5 
2Women’s and Children’s Division Lyell McEwin Hospital, Adelaide, Australia 6 
3
Womens and Babies Research Centre, University of Newcastle, Australia 7 
4
Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences, 8 
University of Auckland, Auckland, New Zealand 9 
 10 
Address for correspondence: 11 
Prof. Claire T Roberts 12 
Robinson Institute 13 
School of Paediatrics and Reproductive Health 14 
University of Adelaide, Australia 5005 15 




This study aimed to determine the association of AGT1R and AGT2R polymorphisms with 18 
preeclampsia and whether these are affected by environmental factors and fetal sex. Overall 19 
3234 healthy nulliparous women, their partners and babies were recruited prospectively to the 20 
SCOPE study in Adelaide and Auckland. Data analyses were confined to 2121 Caucasian 21 
parent-infant trios, among whom 123 had preeclamptic pregnancies. 1185 uncomplicated 22 
pregnancies served as controls. DNA was extracted from buffy coats and genotyped by 23 
utilizing the Sequenom MassARRAY system. Doppler sonography on the uterine arteries was 24 
performed at 20 weeks’ gestation. When the cohort was stratified by maternal BMI, in 25 
women with BMI≥25kg/m2, the AGT2R C4599A AA genotype in mothers and neonates was 26 
associated with an increased risk for preeclampsia compared with the CC genotype [OR 2.1 27 
(95% CI 1.0-4.2) and OR 3.0 (95% CI 1.4-6.5), respectively]. In the same subset of women, 28 
paternal AGT2R C4599A A allele was associated with an increased risk for preeclampsia and 29 
uterine artery bilateral notching at 20 weeks’ gestation compared with the C allele [OR 1.9 30 
(95% CI 1.1-3.2) and OR 2.1 (95% CI 1.3-3.4), respectively]. AGT2R C4599A in mothers, 31 
fathers and babies was associated with preeclampsia and this association was only apparent in 32 
pregnancies in which the women had a BMI≥25kg/m2, suggesting a gene-environment 33 
interaction. 34 
Key words: AGT2R C4599A; AGT2R A1675G; polymorphism; BMI; preeclampsia; uterine 35 
artery bilateral notching 36 
Abbreviation: RAS: renin angiotensin system; AGT2R: angiotensin II type II receptor; 37 
SCOPE: SCreening fOr Pregnancy Endpoints; sBP, systolic blood pressure; dBP, diastolic 38 




Preeclampsia affects up to 7% of nulliparous pregnancies and is a major cause of maternal 41 
and perinatal morbidity and mortality worldwide [1, 2]. To date, the exact cause of 42 
preeclampsia is still unknown. Since hypertension is both a risk factor and a symptom of 43 
preeclampsia, the renin angiotensin system (RAS), which plays an important role in blood 44 
pressure regulation, electrolyte and volume homeostasis [3], has been studied intensively for 45 
its contribution to the development of the disorder. 46 
In third trimester preeclamptic women are reported to have reduced plasma renin activity [4], 47 
increased serum angiotensin converting enzyme (ACE) activity [4], reduced angiotensin II 48 
(ANG II) concentration [4] and increased responsiveness to ANG II [5, 6] compared to 49 
women with normal pregnancy. The aberrant RAS levels/activities observed in preeclamptic 50 
pregnancies may indicate the involvement of RAS in the pathogenesis of preeclampsia. 51 
Therefore, genetic polymorphisms in the RAS components, which modulate RAS 52 
levels/activities, may potentially predispose women to preeclampsia. 53 
Over the past decade, several polymorphisms in the AGT1R and AGT2R genes have been 54 
identified. AGT1R A1166C (rs5186) is located in the 3’ UTR of AGT1R on the chromosome 3. 55 
The AGT1RA1166C CC genotype is associated with greater ANG II responsiveness [7] and 56 
increases risk for coronary artery disease and myocardial infarction [8] compared with the 57 
AA genotype. AGT2R C4599A (rs11091046), AGT2R A1675G (rs1403543) and AGT2R 58 
T1134C (rs12710567) are located in the 3’ UTR of exon 3, intron 1 and the promoter region 59 
of the AGT2R gene on the X chromosome, respectively. The AGT2R A1675G G allele is 60 
associated with higher AGT2R expression compared with the A allele [9]. The functional 61 
effects of AGT2R C4599A and AGT2R T1334C on AGT2R have not been investigated 62 
previously. AGT2R A1675G and AGT2R C4599A have been shown to be in linkage 63 
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disequilibrium in a Japanese population [10]. In a Chinese cohort, the AGT2R T1334C C 64 
allele is associated with an increased risk for essential hypertension compared with the T 65 
allele [11]. 66 
In the current study, our primary aim was to determine if the aforementioned AGT1R and 67 
AGT2R polymorphisms in mothers, fathers and babies were associated with preeclampsia. 68 
Since assessing gene-environment interactions is becoming an increasingly important aspect 69 
of genetic association studies [12, 13], our secondary aim was to determine whether the 70 
association of AGT1R and AGT2R polymorphisms with preeclampsia is affected by risk 71 
factors for preeclampsia, including maternal age [14, 15], BMI [16], green leafy vegetable 72 
intake [17], fruit intake [18], socioeconomic status [19] and smoking [20]. In addition, since 73 
RAS components are sexually dimorphic in adults [21], we explored our primary and 74 
secondary aims in pregnancies bearing female and male infants separately. 75 
  76 
5 
 
Materials and Methods: 77 
Ethics approval 78 
In Australia, ethical approval was obtained from the Central Northern Adelaide Health 79 
Service Ethics of Human Research Committee (study number: REC 1714/5/2008). In New 80 
Zealand, ethical approval was given by the Northern Region Ethics Committee (study 81 
number: AKX/02/00/364). All participants provided written informed consent. Australian 82 
clinical trial registry number: ACTRN 12607000551493 83 
Participants 84 
The participants were healthy nulliparous women with singleton pregnancies recruited to the 85 
Screening for Pregnancy Endpoints (SCOPE) study between November 2004 and September 86 
2008 in Adelaide, Australia and Auckland, New Zealand [22]. SCOPE is a prospective, 87 
multicentre cohort study with the main aim of developing screening tests to predict 88 
preeclampsia, small for gestational age infants and spontaneous preterm birth. Overall 3196 89 
women, their partners and babies were recruited into the study. The population for this 90 
genetic study was confined to the 2121 Caucasian parent-infant trios (66%) (Figure 1).  91 
Women were recruited to the SCOPE study through hospital antenatal clinics, obstetricians, 92 
general practitioners, community midwives and self referral in response to advertisements or 93 
recommendations of friends. Women were excluded if they were judged to be at high risk of 94 
preeclampsia, small for gestational age babies or spontaneous preterm birth because of 95 
underlying medical conditions, gynaecological history, three or more previous miscarriages 96 
or three or more terminations of pregnancy or if they had received interventions that might 97 
modify pregnancy outcome [22]. 98 
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Participants were interviewed and examined by a research midwife at 15±1 weeks of 99 
gestation. Maternal demographic and dietary information was collected, including ethnicity, 100 
age, height, weight, birth weight, gestational age at birth, socio-economic index (SEI
1
)[23], 101 
smoking status at 15 weeks’ gestation and pre-pregnancy green leafy vegetable intake. Two 102 
consecutive manual blood pressure measurements were recorded. Paternal information, 103 
including age, birth weight, height and weight, were also recorded. Newborn measurements 104 
were recorded by research midwives usually within 72 hours of birth. The recorded 105 
parameters included infant’s gestational age at birth, body length, head circumference, mid 106 
arm circumference, birth weight and customised birthweight centile. Ultrasound and Doppler 107 
studies of the umbilical and uterine arteries were performed at 20 weeks’ gestation [24]. 108 
Bilateral notching is defined as the presence of early diastolic notching in the waveform of 109 
both uterine arteries [25]. 110 
Sample collection 111 
Whole blood was collected in EDTA tubes from women at 15 ±1 weeks of gestation, from 112 
partners at some time during the woman’s pregnancy and umbilical cord after delivery. Blood 113 
samples were centrifuged and plasma and buffy coat separated and stored within 3 hours of 114 
collection. Buccal swabs or saliva samples were collected from partners who were unwilling 115 
to undergo venepuncture and babies whose cord blood was not obtained at delivery. The 116 
buccal swabs were applied to Whatman FTA cards (Whatman, USA) immediately following 117 
sample collection and saliva was collected using Oragene kits (DNA genotek, USA). 118 
Pregnancy outcome definitions 119 
                                                 
1 The New Zealand socio-economic index of occupational status, a number between 10 and 90 and is an occupationally 
derived indicator of socio-economic status. It is a validated measure of an individual’s socioeconomic status and a higher 
score indicates higher socio-economic status. 
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Preeclampsia was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure 120 
≥90 mm Hg, or both, on at least two occasions four hours apart after 20 weeks’ gestation but 121 
before the onset of labour or postpartum, with either proteinuria (24 hour urinary 122 
protein >300mg or spot urine protein: creatinine ratio >30mg/mmol creatinine or urine 123 
dipstick protein >++) or any multisystem complication of preeclampsia [18].  124 
Uncomplicated pregnancies were those without any pregnancy complication and with delivery 125 
of an appropriately grown baby at term. 126 
Genotyping assays  127 
DNA was extracted from buffy coats isolated from peripheral or cord blood (QiAamp 96 128 
DNA blood kit), Whatman FTA cards or from saliva (Oragene
®
DNA kits) following the 129 
manufacturers’ instructions. Genotyping was performed by the Australian Genome Research 130 
Facility (AGRF) utilizing the Sequenom MassARRAY system. Two quality control 131 
procedures were in place to ensure the accuracy of genotyping data: 1) Each sample was 132 
genotyped for Amelogenin to assess the consistency between the sex of samples and the 133 
corresponding Amelogenin genotype [26]. 2) Parental and neonatal genotyping data were 134 
checked for a Mendelian pattern of inheritance. The samples with inconsistent results in either 135 
step were excluded from the analyses. In addition, some samples were excluded due to 136 
inadequate blood samples, low quality of DNA or failure to genotype. The sample sizes for 137 
the genotyping data are shown in the results tables. 138 
Statistics 139 
Chi-square test was used to test the genotypes at each polymorphic locus for Hardy-Weinberg 140 
Equilibrium (HWE). Independent samples t test (for continuous variables) and chi-square (for 141 
categorical variables) were used to compare characteristics between uncomplicated 142 
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pregnancies and preeclampsia. The association of polymorphisms with preeclampsia and 143 
uterine artery bilateral notching was assessed by using logistic regression and odds ratios (OR) 144 
were generated. All data analyses were performed using PASW (SPSS, Chicago) version 145 
17.02. P<0.05 was considered statistically significant. 146 




Study population 149 
Of the 3234 recruited women, 1113 (34%) women were excluded due to one of the reasons 150 
shown in figure 1. The final analyses were conducted on 2121 Caucasian women, consisting 151 
of 1185 (55.9%) women with uncomplicated pregnancies, 123 (5.8%) preeclamptic women 152 
and 813 (38.3%) women with other complications. 153 
For the 2121 Caucasian parent-infant trios, genotype data of up to 199 (9.4%) women, 470 154 
(22.2%) partners and 578 (27.3%) infants could not be analysed for one of the following 155 
reasons: non availability of samples, genotyping failure or Mendelian inconsistencies in 156 
parent-infant genotypes. The available genotype data of each polymorphism for 157 
uncomplicated and preeclamptic pregnancies are shown in table 2. 158 
Characteristics of the population 159 
Women who later developed preeclampsia were on average younger, heavier, had higher sBP 160 
and dBP at 15 weeks’ gestation, were less likely to consume ≥1 serve/day of fruit and green 161 
vegetables prior to pregnancy and they themselves weighed less at birth than the women with 162 
uncomplicated pregnancies (Table 1). Partners who fathered a preeclamptic pregnancy on 163 
average were younger and heavier than those with uncomplicated pregnancies. Infants born 164 
to preeclamptic pregnancies were smaller (adjusted for gestational age where appropriate) in 165 
all neonatal measures than those born to uncomplicated pregnancies (Table 1). In addition, 166 
there was no difference in sex ratio between preeclampsia and uncomplicated pregnancy 167 
groups (Table 1). 168 




The analyses for the association of polymorphisms with preeclampsia were performed 171 
comparing the uncomplicated and preeclampsia groups (Figure 1). The association of 172 
polymorphisms with uterine artery bilateral notching at 20 weeks’ gestation were analysed in 173 
uncomplicated, preeclampsia and other complications group (Figure 1). For subgroup 174 
analyses, the cohort was stratified by environmental factors, including maternal age (age <29 175 
years versus ≥29 years), maternal BMI (BMI <25kg/m2 versus ≥25kg/m2), SEI (SEI <34 176 
versus ≥34), pre-pregnancy green leafy vegetable intake (vegetable intake <1 serve/day 177 
versus ≥1 serve/day), pre-pregnancy fruit intake (fruit intake <1 serve/day versus ≥1 178 
serve/day) and smoking status at 15 weeks’ gestation (no smoking versus smoking).  179 
Since AGT2R is on the X chromosome, male partners only have one allele of the AGT2R 180 
polymorphisms. Accordingly, analyses on partners were performed in the fashion of alleles. 181 
Male neonates also have one allele of the AGT2R polymorphisms, however, since sample size 182 
of male neonates was small, we grouped it with female neonates and data were analysed in 183 
the fashion of genotypes. Take the AGT2R C4599A polymorphism as an example, male 184 
neonates with C allele were allocated to the CC genotype group and those with A allele were 185 
allocated to the AA genotype group. 186 
AGT1R A1166C and AGT2R T1334C 187 
Since the frequency of maternal and neonatal AGT2R T1334C CC genotype was less than 3%, 188 
the CC and CT genotype were combined. AGT1R A1166C and AGT2R T1334C were not 189 
associated with preeclampsia nor with uterine artery bilateral notching at 20 weeks’ gestation 190 
(Table 2). 191 
  192 
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AGT2R C4599A 193 
AGT2R C4599A in mothers, partners and neonates was not associated with preeclampsia nor 194 
with uterine artery bilateral notching at 20 weeks’ gestation (Table 2). However, when the 195 
cohort was stratified by maternal BMI using 25kg/m
2
 as the cut-off point, among women 196 
with BMI≥25kg/m2, maternal AGT2R C4599A AA genotype and paternal AGT2R C4599A A 197 
allele were associated with an increased risk for preeclampsia with OR 2.1 (95% CI 1.0-4.2) 198 
and OR 1.9 (95% CI 1.1-3.2), respectively (Table 3). In neonates, AGT2R C4599A CA and 199 
AA genotype both increased the risk for preeclampsia in women with BMI ≥25kg/m2 with 200 
OR 3.5 (95% CI 1.6-7.9) and OR 3.0 (95% CI 1.4-6.5), respectively (Table 3). In addition, 201 
the paternal AGT2R C4599A A allele was also associated with an increased risk for uterine 202 
artery bilateral notching at 20 weeks’ gestation [OR 2.1 (95% CI 1.3-3.4)] (Table 3). 203 
AGT2R A1675G 204 
AGT2R A1675G was not associated with preeclampsia nor with uterine artery bilateral 205 
notching at 20 weeks’ gestation (Table 2). When the cohort was stratified by maternal BMI, 206 
among women with BMI≥25kg/m2, neonatal AGT2R A1675G AG genotype was associated 207 
with an increased risk for preeclampsia with OR 2.5 (95% CI 1.2-5.4). There was a trend for 208 
maternal GG genotype, paternal G allele and neonatal GG genotype of AGT2R A1675G to 209 
associate with an increased risk for preeclampsia (Table 4). In addition, among women with 210 
BMI≥25kg/m2, paternal AGT2R A1675G G allele increased the risk for uterine artery bilateral 211 
notching [OR 1.6 (95% CI 1.0-2.7] (Table 4). Moreover, neonatal AGT2R A1675G GG 212 
genotype also tended to associate with an increased risk for uterine artery bilateral notching 213 




In the current study, in women with BMI≥25kg/m2, maternal, paternal and neonatal AGT2R 216 
C4599A was associated with preeclampsia. In the same subset of women, a similar non-217 
significant trend was also observed for maternal, paternal and neonatal AGT2R A1675G, 218 
which has previously been shown to be in linkage disequilibrium with AGT2R C4599A [10]. 219 
Furthermore, in women with BMI≥25kg/m2, paternal AGT2R C4599A A allele and paternal 220 
AGT2R A1675G G allele were associated with an increased risk for uterine artery bilateral 221 
notching at 20 weeks’ gestation. 222 
The observed association of maternal AGT2R C4599A with preeclampsia is consistent with a 223 
recent Romanian study [27], in which women bearing the AGT2R C4599A AA genotype were 224 
at an increased risk of developing preeclampsia with OR 3.8 (95% CI 1.1-12.5). The 225 
novelties of the current study include 1) paternal and neonatal association of this 226 
polymorphism with preeclampsia and 2) modulation of these associations by maternal BMI. 227 
Epidemiological studies have shown that the risk of preeclampsia is determined not only by 228 
maternal predisposition, but also by a paternal contribution. Men born to a preeclamptic 229 
pregnancy are twice as likely to father a preeclamptic pregnancy [28]. In addition, men who 230 
have fathered a preeclamptic pregnancy are nearly twice as likely to father a preeclamptic 231 
pregnancy with a different woman, regardless of whether she has already had a preeclamptic 232 
pregnancy or not [29]. The paternal and neonatal association of AGT2R C4599A with 233 
preeclampsia observed in the current study provides further evidence for the paternal genetic 234 
contribution to preeclampsia. 235 
The mechanism behind the association of AGT2R C4599A with preeclampsia is yet to be 236 
determined. However, since the association was found in fathers and neonates and since the 237 
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polymorphism in fathers was also associated with uterine artery bilateral notching, an 238 
indication of high uterine artery resistance and inadequate trophoblast invasion [25], the 239 
placenta is likely to be involved. The expression of AGT2R in the placenta has been 240 
documented across gestation [30, 31], however, its role in placentation is poorly understood. 241 
Since AGT2R has been shown to induce apoptosis in various cells types [32-34] and 242 
preeclampsia is characterised by an increased rate of trophoblast apoptosis [35, 36], it is 243 
tempting to speculate that trophoblast apoptosis may hold the key to the association of 244 
AGT2R C4599A with preeclampsia. Furthermore, since AGT2R A1675G, known to be in 245 
linkage disequilibrium with AGT2R C4599A [10], associates with AGT2R expression in vitro 246 
[9], one would expect such an association for AGT2R C4599A, that is, the A allele of AGT2R 247 
C4599A is associated with higher AGT2R expression. Taken all together, the A allele or AA 248 
genotype of AGT2R C4599A in parent-infant trios, which may associate with higher AGT2R 249 
expression in the placenta, potentially links to an increased rate of trophoblast apoptosis and 250 
consequently leads to an increased risk for preeclampsia. 251 
Gene-environment interaction describes the phenomenon in which association of a genetic 252 
variant with a disease phenotype varies with the degree of exposure to an environmental 253 
factor or vice versa. In the current study, the associations of AGT2R polymorphisms with 254 
preeclampsia and uterine artery bilateral notching at 20 weeks’ gestation were only observed 255 
among women with BMI≥25kg/m2 but not among those with BMI<25kg/m2, suggesting an 256 
interaction between AGT2R polymorphisms and maternal BMI. Elevated BMI is a well 257 
established risk factor for preeclampsia [37]. In our SCOPE cohort, for every 5 units 258 
increment in maternal BMI, there is a 1.3-fold increase in risk for preeclampsia [18]. The 259 
AGT2R-BMI interaction observed in the current study may suggest that the adverse effects 260 
associated with AGT2R C4599A A allele or AA genotype are subtle and can only place 261 
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women at risk for preeclampsia or uterine artery bilateral notching if superimposed on 262 
adverse effects associated with elevated BMI such as chronic inflammation [38]. 263 
The strength of this study is its large multicentre prospective design. In addition, the outcome 264 
data of these cases were reviewed by highly skilled SCOPE clinicians to ensure accurate 265 
diagnosis. The weakness of the study is the missing genotypes of some participants, which 266 
reduced our sample size and may potentially introduce bias into our results. However, there 267 
are no systematic reasons for missing genotypes identified. In addition, in order to strengthen 268 
the reliability of our results, independent cohorts are required to replicate our findings. 269 
In summary, we have shown that AGT2R C4599A in mothers, fathers and neonates is 270 
associated with preeclampsia. The association was further strengthened by its association 271 
with uterine artery bilateral notching at 20 weeks’ gestation, an indication of poor placental 272 
blood flow. More interestingly, these associations were modulated by maternal BMI and only 273 
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Figure 1 Flow chart of participant recruitment. 
Conceived using donor gametes (n=19) 
 
Lost to follow up (n=26) 
Parental ethnicity non Caucasian (n=437) 
Preeclampsia n=123 
Women recruited into SCOPE study 
n=3234 
Excluded due to protocol violation (n=12) 
Partner did not consent (n=591) 
 
Study population at 15±1 weeks  
n=3196 
Miscarriage or termination (n=28) 
 
Eligible study population (parent-infant trio)  
n=2121 
Uncomplicated n=1185 Other complications n=813 
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Maternal characteristics n=1185 n=123 P 
 
Age (yrs)* 28.2 (5.6) 26.8 (5.4) 0.007 
 
BMI (kg/m2)* 24.9 (4.5) 28.2 (7.2) <0.001 
 
sBP (mmHg)* 106.2 (9.9) 113.0 (10.1) <0.001 
 
dBP (mmHg)* 63.3 (7.6) 68.9 (8.1) <0.001 
 
Socio-economic index 41.9 (16.7) 36.5 (16.0) 0.001 
 
Pre-pregnancy green leafy vegetable 
intake ≥1 serve/day (%) 615 (51.9%) 51 (41.5%) 0.03 
 
Pre-pregnancy fruit intake ≥1 
serve/day (%) 751 (63.4%) 66 (53.7%) 0.03 
 
Smoking (%)* 111 (9.4%) 12 (9.8%) 0.9 
 
Maternal gestational age (wks) 39.9 (1.9) 39.5 (2.2) 0.1 
 
Maternal birth weight (g) 3334.6 (529.7) 3176.6 (543.6) 0.02* 
Paternal characteristics n=1182 n=123 
 
 
Age (yrs) 30.7 (6.3) 29.1 (5.6) 0.005 
 
Height (cm) 179.6 (6.7) 179.2 (6.9) 0.5 
 
BMI (kg/m2) 26.6 (4.0) 28.3 (5.5) 0.001 
 
Paternal birth weight (g) 3487.8 (571.4) 3506.5 (552.6) 0.7 
Newborn characteristics n=1185 n=123 
 
 
Gestational age at birth (days) 280.7 (8.1) 266.0 (17.7) <0.001 
 
Body length (cm) 51.0 (2.2) 48.4 (3.8) <0.001** 
 
Head circumference (mm) 35.2 (1.4) 33.8 (2.3) <0.001** 
 
Mid arm circumference (mm) 11.0 (0.9) 10.1 (1.5) <0.001** 
 
Birth weight (g) 3590.9 (393.8) 3078.4 (747.8) <0.001** 
 
Customised birthweight centile 53.7 (25.0) 44.8 (32.1) 0.004 
 
Female babies (%) 584 (49.3%) 64 (52%) 0.6 
Data are presented as mean (SD) or n (%).*measurements were taken at 15 week’s gestation. **adjusted for 
gestational age. sBP: systolic blood pressure, the second measurement; dBP: diastolic blood pressure, the 
second measurement. Bold italics indicate significant difference. 
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Table 2 The association of AGT1R and AGT2R polymorphisms with preeclampsia and 
uterine artery bilateral notching at 20 weeks’ gestation. 
  Uncomplicated Preeclampsia OR (95% CI)   No bilateral notching Bilateral notching OR (95% CI) 




AA 525 (49.2%) 59 (51.3%) Ref 
 
839 (48.9%) 99 (49.0%) Ref 
CA 445 (41.7%) 50 (43.5%) 1.0 (0.7-1.5) 
 
736 (42.9%) 78 (38.6%) 0.9 (0.7-1.2) 
CC 98 (9.2%) 6 (5.2%) 0.6 (0.2-1.3)   141 (8.2%) 25 (12.4%) 1.5 (0.9-2.4) 




AA 443 (46.6%) 50 (49.5%) Ref 
 
715 (47.4%) 88 (49.4%) Ref 
CA 412 (43.3%) 43 (42.6%) 0.9 (0.6-1.4) 
 
660 (43.7%) 71 (39.9%) 0.9 (0.6-1.2) 
CC 96 (10.1%) 8 (7.9%) 0.7 (0.3-1.6)   135 (8.9%) 19 (10.7%) 1.1 (0.7-1.9) 




AA 451 (49.5%) 51 (56.7%) Ref 
 
677 (49.6%) 77 (44.8%) Ref 
CA 381 (41.8%) 32 (35.6%) 0.7 (0.5-1.2) 
 
576 (42.2%) 81 (47.1%) 1.2 (0.9-1.7) 
CC 80 (8.8%) 7 (7.8%) 0.8 (0.3-1.8)   113 (8.3%) 14 (8.1%) 1.1 (0.6-2.0) 




CC 280 (26.1%) 24 (20.5%) Ref 
 
457 (26.5%) 49 (23.8%) Ref 
CA 545 (50.7%) 59 (50.4%) 1.3 (0.8-2.1) 
 
884 (51.2%) 99 (48.1%) 1.1 (0.7-1.5) 
AA 249 (23.2%) 34 (29.1%) 1.6 (0.9-2.8)   386 (22.4%) 58 (28.2%) 1.4 (0.9-2.1) 




C allele 508 (52.2%) 47 (46.5%) Ref 
 
814 (52.9%) 80 (46.0%) Ref 
A allele 466 (47.8%) 54 (53.5%) 1.3 (0.8-1.9)   726 (47.1%) 94 (54.0%) 1.3 (1.0-1.8) 




CC 358 (37.6%) 24 (27.3%) Ref 
 
531 (37.4%) 66 (36.7%) Ref 
CA 232 (24.4%) 24 (27.3%) 1.5 (0.9-2.8) 
 
371 (26.1%) 46 (25.6%) 1.0 (0.7-1.5) 
AA 361 (38.0%) 40 (45.5%) 1.7 (1.0-2.8)   517 (36.4%) 68 (37.8%) 1.1 (0.7-1.5) 




AA 277 (25.6%) 24 (20.2%) Ref 
 
442 (25.5%) 50 (24.2%) Ref 
AG 544 (50.2%) 61 (51.3%) 1.3 (0.8-2.1) 
 
888 (51.3%) 94 (45.4%) 0.9 (0.7-1.4) 
GG 263 (24.3%) 34 (28.6%) 1.5 (0.9-2.6)   402 (23.2%) 63 (30.4%) 1.4 (0.9-2.1) 




A allele 479 (51.5%) 46 (46.9%) Ref 
 
760 (51.3%) 79 (47.6%) Ref 
G allele 452 (48.5%) 52 (53.1%) 1.2 (0.8-1.8)   722 (48.7%) 87 (52.4%) 1.2 (0.8-1.6) 




AA 330 (36.0%) 26 (29.9%) Ref 
 
509 (36.8%) 51 (31.3%) Ref 
AG 225 (24.5%) 25 (28.7%) 1.4 (0.8-2.5) 
 
350 (25.3%) 44 (27.0%) 1.3 (0.8-1.9) 
GG 362 (39.5%) 36 (41.4%) 1.3 (0.8-2.1)   525 (37.9%) 68 (41.7%) 1.3 (0.9-1.9) 




TT 1011 (93.2%) 108 (90.8%) Ref 
 
1620 (93.4%) 192 (92.8%) Ref 
CT&CC 74 (6.8%) 11 (9.2%) 1.4 (0.7-2.7)   115 (6.6%) 15 (7.2%) 1.1 (0.6-1.9) 




T allele 964 (97.0%) 98 (94.2%) Ref 
 
1524 (97.2%) 171 (95.5%) Ref 
C allele 30 (3.0%) 6 (5.8%) 2.0 (0.8-4.8)   44 (2.8%) 8 (4.5%) 1.6 (0.8-3.5) 




TT 914 (95.1%) 88 (94.6%) Ref 
 
1374 (95.2%) 167 (94.9%) Ref 
CT&CC 47 (4.9%) 5 (5.4%) 1.1 (0.4-2.9)   70 (4.8%) 9 (5.1%) 1.1 (0.5-2.2) 
Data are presented as n (%).*CC genotype = female neonatal CC genotype + male neonatal C allele; CA 
genotype = female neonatal CA genotype; AA genotype = female neonatal AA genotype + male neonatal A 
allele. **AA genotype = female neonatal AA genotype + male neonatal A allele; AG genotype = female 
neonatal AG genotype; GG genotype = female neonatal GG genotype + male neonatal G allele. ***TT genotype 
= female neonatal TT genotype + male neonatal T allele; CT&CC genotype= female neonatal CT & CC 
genotype + male neonatal C allele. 
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Table 3 The association of AGT2R C4599A with preeclampsia and uterine artery bilateral notching at 20 weeks’ gestation, stratified by maternal 
BMI. 
Maternal BMI Maternal AGT2R C4599A n Uncomplicated Preeclampsia OR (95% CI)   n No bilateral notching Bilateral notching OR (95% CI) 
BMI<25kg/m2 CC 153 143 (93.5%) 10 (6.5%) Ref 
 
236 211 (89.4%) 25 (10.6%) Ref 
 
CA 333 308 (92.5%) 25 (7.5%) 1.2 (0.5-2.5) 
 
490 431 (88.0%) 59 (12.0%) 1.2 (0.7-1.9) 
 
AA 152 141 (92.8%) 11 (7.2%) 1.1 (0.5-2.7) 
 
214 184 (86.0%) 30 (14.0%) 1.4 (0.8-2.4) 
BMI≥25kg/m2 CC 151 137 (90.7%) 14 (9.3%) Ref 
 
270 246 (91.1%) 24 (8.9%) Ref 
 
CA 271 237 (87.5%) 34 (12.5%) 1.4 (0.7-2.7) 
 
493 453 (91.9%) 40 (8.1%) 0.9 (0.5-1.5) 
  AA 131 108 (82.4%) 23 (17.6%) 2.1 (1.0-4.2)  230 202 (87.8%) 28 (12.2%) 1.4 (0.8-2.5) 
 
Paternal AGT2R C4599A 
         BMI<25kg/m2 C allele 294 272 (92.5%) 22 (7.5%) Ref 
 
430 379 (88.1%) 51 (11.9%) Ref 
 
A allele 282 267 (94.7%) 15 (5.3%) 0.7 (0.4-1.4) 
 
402 360 (89.6%) 42 (10.4%) 0.9 (0.6-1.3) 
BMI≥25kg/m2 C allele 261 236 (90.4%) 25 (9.6%) Ref 
 
464 435 (93.8%) 29 (6.3%) Ref 
  A allele 238 199 (83.6%) 39 (16.4%) 1.9 (1.1-3.2)   418 366 (87.6%) 52 (12.4%) 2.1 (1.3-3.4) 
 
Neonatal AGT2R C4599A* 
         BMI<25kg/m2 CC 184 170 (92.4%) 14 (7.6%) Ref 
 
276 241 (87.3%) 35 (12.7%) Ref 
 
CA 141 135 (95.7%) 6 (4.3%) 0.5 (0.2-1.4) 
 
215 188 (87.4%) 27 (12.6%) 1.0 (0.6-1.7) 
 
AA 233 216 (92.7%) 17 (7.3%) 1.0 (0.5-2.0) 
 
311 272 (87.5%) 39 (12.5%) 1.0 (0.6-1.6) 
BMI≥25kg/m2 CC 198 188 (94.9%) 10 (5.1%) Ref 
 
321 290 (90.3%) 31 (9.7%) Ref 
 
CA 115 97 (84.3%) 18 (15.7%) 3.5 (1.6-7.9) 
 
202 183 (90.6%) 19 (9.4%) 1.0 (0.5-1.8) 
  AA 168 145 (86.3%) 23 (13.7%) 3.0 (1.4-6.5)  274 245 (89.4%) 29 (10.6%) 1.1 (0.7-1.9) 
Data are presented as n (%). Bold italics indicate significant difference. *CC genotype = female neonatal CC genotype + male neonatal C allele; CA genotype = female 
neonatal CA genotype; AA genotype = female neonatal AA genotype + male neonatal A allele. 
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Table 4 The association of AGT2R A1657G with preeclampsia and uterine artery bilateral notching at 20 weeks’ gestation, stratified by maternal 
BMI. 
Maternal BMI Maternal AGT2R A1675G n Uncomplicated Preeclampsia OR (95% CI)   n No bilateral notching Bilateral notching OR (95% CI) 
BMI<25kg/m2 AA 149 139 (93.3%) 10 (6.7%) Ref 
 
233 208 (89.3%) 25 (10.7%) Ref 
 
AG 333 308 (92.5%) 25 (7.5%) 1.1 (0.5-2.4) 
 
489 433 (88.5%) 56 (11.5%) 1.1 (0.7-1.8) 
 
GG 163 151 (92.6%) 12 (7.4%) 1.1 (0.5-2.6) 
 
225 193 (85.8%) 32 (14.2%) 1.4 (0.8-2.4) 
BMI≥25kg/m2 AA 152 138 (90.8%) 14 (9.2%) Ref 
 
259 234 (90.3%) 25 (9.7%) Ref 
 
AG 272 236 (86.8%) 36 (13.2%) 1.5 (0.8-2.9) 
 
493 455 (92.3%) 38 (7.7%) 0.8 (0.5-1.3) 
  GG 134 112 (83.6%) 22 (16.4%) 1.9 (1.0-4.0)  240 209 (87.1%) 31 (12.9%) 1.4 (0.8-2.4) 
 
Paternal AGT2R A1675G 
         BMI<25kg/m2 A allele 276 255 (92.4%) 21 (7.6%) Ref 
 
395 347 (87.8%) 48 (12.2%) Ref 
 
G allele 267 253 (94.8%) 14 (5.2%) 0.7 (0.3-1.4) 
 
390 349 (89.5%) 41 (10.5%) 0.9 (0.6-1.3) 
BMI≥25kg/m2 A allele 249 224 (90.0%) 25 (10.0%) Ref 
 
444 413 (93.0%) 31 (7.0%) Ref 
  G allele 237 199 (84.0%) 38 (16.0%) 1.7 (1.0-2.9)  419 373 (89.0%) 46 (11.0%) 1.6 (1.0-2.7) 
 
Neonatal AGT2R A1675G 
         BMI<25kg/m2 AA 170 157 (92.4%) 13 (7.6%) Ref 
 
253 225 (88.9%) 28 (11.1%) Ref 
 
AG 137 130 (94.9%) 7 (5.1%) 0.7 (0.3-1.7) 
 
203 177 (87.2%) 26 (12.8%) 1.2 (0.7-2.1) 
 
GG 236 220 (93.2%) 16 (6.8%) 0.9 (0.4-1.9) 
 
318 279 (87.7%) 39 (12.3%) 1.1 (0.7-1.9) 
BMI≥25kg/m2 AA 186 173 (93.0%) 13 (7.0%) Ref 
 
307 284 (92.5%) 23 (7.5%) Ref 
 
AG 113 95 (84.1%) 18 (15.9%) 2.5 (1.2-5.4) 
 
191 173 (90.6%) 18 (9.4%) 1.3 (0.7-2.5) 
  GG 162 142 (87.7%) 20 (12.3%) 1.9 (0.9-3.9)  275 246 (89.5%) 29 (10.5%) 1.5 (0.8-2.6) 
Data are presented as n (%). Bold italics indicate significant difference. *AA genotype = female neonatal AA genotype + male neonatal A allele; AG genotype = female 
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